Entrectinib
Use attributes for filter ! | |
Molar mass | 560. 64 g/mol |
---|---|
Trade name | Rozlytrek |
Other names | RXDX-101, NMS-E628 |
Drug class | Antineoplastic agent |
ATC code | WHO |
License data | DailyMed |
US | |
FDA | |
Date of Reg. | |
Date of Upd. | |
ID | 2951343 |
About Entrectinib
Entrectinib is an anti-cancer drug used to treat ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors. It was approved in the United States on 15 August 2019.